Abnormalities of the PRMT1-ADMA-DDAH1 metabolism axis and probucol treatment in diabetic patients and diabetic rats | Zendy

Xi Mei | Zendy; Jun Zeng | Zendy; Dongfang Liu | Zendy; Ye Zhao | Zendy; Huilan Yang | Zendy; Yao Li | Zendy; Ping Qiu | Zendy; Mingwei Tang | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Abnormalities of the PRMT1-ADMA-DDAH1 metabolism axis and probucol treatment in diabetic patients and diabetic rats

Author(s) -

Xi Mei,

Jun Zeng,

Dongfang Liu,

Ye Zhao,

Huilan Yang,

Yao Li,

Ping Qiu,

Mingwei Tang

Publication year - 2021

Publication title -

annals of palliative medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.546

H-Index - 19

eISSN - 2224-5839

pISSN - 2224-5820

DOI - 10.21037/apm-21-417

Subject(s) - asymmetric dimethylarginine , medicine , probucol , arginine , endocrinology , metabolism , diabetes mellitus , nitric oxide , nitric oxide synthase , type 2 diabetes , biochemistry , amino acid , chemistry , cholesterol

Symmetrical dimethylarginine (ADMA) endogenously inhibits nitric oxide synthase (NOS) and strongly indicates oxidant stress, whose formation primarily derived from type 1 protein arginine N-methyltransferase (PRMT1) and whose metabolism was governed by type 1 dimethylarginine dimethylaminohydrolase (DDAH1). This study aimed to evaluate participation of the PRMT1-ADMA-DDAH1 metabolism axis in the kidneys of type 2 diabetes model rats and human subjects, and the effect of probucol on this axis and renal function.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research